Venaxis Inc  

(Public, NASDAQ:APPY)   Watch this stock  
Find more results for APPY
+0.050 (10.20%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.50 - 0.59
52 week 0.40 - 3.88
Open 0.50
Vol / Avg. 3.61M/1.01M
Mkt cap 16.73M
P/E     -
Div/yield     -
EPS -0.45
Shares 30.99M
Beta 1.27
Inst. own 18%
Jan 12, 2015
Venaxis Inc at EBD Biotech Showcase
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -6979.01% -21666.95%
Operating margin -7009.73% -21585.84%
EBITD margin - -20944.62%
Return on average assets -31.62% -68.92%
Return on average equity -37.49% -102.78%
Employees 20 -
CDP Score - -


1585 South Perry Street
United States - Map
+1-303-7942000 (Phone)
+1-303-7988332 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Venaxis, Inc., formerly AspenBio Pharma, Inc., is focused on products that address unmet human diagnostic needs. The Company is developing a multi-marker blood test panel, APPY1, which is focused to be used by emergency department and urgent care physicians to aid them in the evaluation of possible appendicitis in children, adolescent and young adult patients (ages 2-20) that present with abdominal pain. As on December 31, 2013, the Company�s research and development activities are focused primarily on a human acute appendicitis blood-based test. APPY1 is a multi-marker blood test panel of biomarkers consisting of the Company�s patented MRP 8/14 (also known as S100A8/A9 or calprotectin) and C-reactive protein (CRP), along with White Blood Cell count (WBC). These results are displayed on the display screen and are also included on a patient printout from the APPY reader, which is a small bioanalyzer (instrument or reader).

Officers and directors

Stephen T. Lundy President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Jeffrey G. McGonegal Chief Financial Officer, Corporate Secretary
Age: 63
Bio & Compensation  - Reuters
Gail S. Schoettler Ph.D. Non-Executive Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Susan A. Evans Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters
Daryl Jay Faulkner Independent Director
Age: 65
Bio & Compensation  - Reuters
John H. Landon Independent Director
Age: 73
Bio & Compensation  - Reuters
David E. Welch Independent Director
Age: 67
Bio & Compensation  - Reuters